公开(公告)号：US10085968B2

公开(公告)日：2018-10-02

申请号：US14950834

申请日：2015-11-24

Applicant: Sunovion Pharmaceuticals, Inc. ,  PGI Drug Discovery LLC

Inventor： Liming Shao ,  John Emmerson Campbell ,  Michael Charles Hewitt ,  Una Campbell ,  Taleen G. Hanania

IPC: C07D233/00 ,  C07D403/02 ,  C07D403/14 ,  C07D231/00 ,  C07D487/02 ,  C07D487/00 ,  C07D405/00 ,  C07D409/00 ,  C07D495/02 ,  A61K31/415 ,  A61K31/40 ,  C07D277/22 ,  A61K31/381 ,  C07D277/60 ,  C07D333/54 ,  C07D333/76 ,  C07D333/78 ,  C07D495/04 ,  C07D495/20 ,  A61K31/435 ,  A61K31/55 ,  A61K45/06

Abstract: Provided herein are multicyclic compounds of formula (IVa), shown below, wherein R1, R2, R3, R4, R5, R6, R7, m, and n are defined herein elsewhere, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

公开(公告)号：US20180148407A1

公开(公告)日：2018-05-31

申请号：US15817760

申请日：2017-11-20

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Liming Shao ,  Fengjiang Wang ,  Scott C. Malcolm ,  Michael C. Hewitt

IPC: C07D209/44 ,  C07D209/52 ,  A61K31/4035 ,  C07D209/08

CPC classification number: C07D209/44 ,  A61K31/4035 ,  C07D209/08 ,  C07D209/52

Abstract: Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.

公开(公告)号：US09868718B2

公开(公告)日：2018-01-16

申请号：US14502532

申请日：2014-09-30

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Liming Shao ,  Fengjiang Wang ,  Scott Christopher Malcolm ,  Michael Charles Hewitt ,  Larry R. Bush ,  Jianguo Ma ,  Mark A. Varney ,  Una Campbell ,  Sharon Rae Engel ,  Larry Wendell Hardy ,  Patrick Koch ,  John E. Campbell

IPC: C07C13/28 ,  C07D333/20 ,  C07C211/17 ,  C07C211/29 ,  C07C211/40 ,  C07C215/42 ,  C07C215/44 ,  C07C217/52 ,  C07C217/74 ,  C07C323/32 ,  C07D207/06 ,  C07D207/08 ,  C07D211/14 ,  C07D265/14 ,  C07D277/28 ,  C07D295/06 ,  C07D307/52 ,  C07D317/58 ,  C07D317/72 ,  C07D319/06 ,  C07D491/056 ,  C07D211/16

CPC classification number: C07D333/20 ,  C07C211/17 ,  C07C211/29 ,  C07C211/40 ,  C07C215/42 ,  C07C215/44 ,  C07C217/52 ,  C07C217/74 ,  C07C323/32 ,  C07C2601/02 ,  C07C2601/08 ,  C07C2601/10 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2602/08 ,  C07D207/06 ,  C07D207/08 ,  C07D211/14 ,  C07D211/16 ,  C07D265/14 ,  C07D277/28 ,  C07D295/06 ,  C07D307/52 ,  C07D317/58 ,  C07D317/72 ,  C07D319/06 ,  C07D491/056

Abstract: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

公开(公告)号：US10894033B2

公开(公告)日：2021-01-19

申请号：US16791118

申请日：2020-02-14

Applicant: Sunovion Pharmaceuticals Inc. ,  PGI Drug Discovery LLC

Inventor： Liming Shao ,  John Emmerson Campbell ,  Michael Charles Hewitt ,  Una Campbell ,  Taleen G. Hanania

IPC: A61K31/381 ,  C07D277/60 ,  C07D333/54 ,  C07D333/76 ,  A61K45/06 ,  C07D495/04 ,  C07D495/20 ,  A61K31/435 ,  A61K31/55 ,  C07D333/78

Abstract: Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

公开(公告)号：US09586888B2

公开(公告)日：2017-03-07

申请号：US14149492

申请日：2014-01-07

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Liming Shao ,  Fengjiang Wang ,  Scott Christopher Malcolm ,  Michael Charles Hewitt ,  Jianguo Ma ,  Seth Ribe ,  Mark A. Varney ,  Una Campbell ,  Sharon Rae Engel ,  Larry Wendell Hardy ,  Patrick Koch ,  Rudy Schreiber ,  Kerry L. Spear

IPC: C07C215/42 ,  C07C217/52 ,  C07C217/76 ,  A61K31/135

CPC classification number: C07C215/42 ,  A61K31/135 ,  A61P25/24 ,  A61P25/28 ,  C07B2200/07 ,  C07C217/52 ,  C07C217/76 ,  C07C2601/14

Abstract: Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.

Abstract translation: 公开了苯基取代的环己胺衍生物及其合成和表征的方法。 本文阐述了这些化合物治疗/预防神经系统疾病及其合成方法的用途。 本发明的示例性化合物抑制内源性单胺如多巴胺，5-羟色胺和去甲肾上腺素的再摄取（例如，从突触腭裂）并调节一种或多种单胺转运蛋白。 还提供了掺入本发明化合物的药物制剂。

公开(公告)号：US09505716B2

公开(公告)日：2016-11-29

申请号：US14726797

申请日：2015-06-01

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Liming Shao ,  Jianguo Ma

IPC: C07D207/08 ,  C07D207/06 ,  A61K31/40 ,  C07D207/12 ,  C07D405/04

CPC classification number: C07D207/06 ,  A61K31/40 ,  C07D207/08 ,  C07D207/12 ,  C07D405/04

Abstract: In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

公开(公告)号：US20160221947A1

公开(公告)日：2016-08-04

申请号：US14850338

申请日：2015-09-10

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Liming Shao ,  Fengjiang Wang ,  Scott C. Malcolm ,  Michael C. Hewitt

IPC: C07D209/44 ,  A61K31/4035

CPC classification number: C07D209/44 ,  A61K31/4035 ,  C07D209/08 ,  C07D209/52

Abstract: Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.

Abstract translation: 本文提供的是双环化合物及其合成方法。 本文提供的化合物可用于治疗，预防和/或管理各种神经障碍。 本文提供的化合物抑制内源性单胺如多巴胺，5-羟色胺和去甲肾上腺素的再摄取（例如，从突触腭裂）并调节一种或多种单胺转运蛋白。 还提供了含有这些化合物的药物制剂。

公开(公告)号：US20150031709A1

公开(公告)日：2015-01-29

申请号：US14377673

申请日：2013-02-08

Applicant: Sunovion Pharmaceuticals, Inc.

Inventor： John Emmerson Campbell ,  Una Campbell ,  Taleen G. Hanania ,  Liming Shao

IPC: C07D409/04 ,  C07D409/14 ,  C07D491/048 ,  C07D405/04 ,  C07D495/04

CPC classification number: C07D409/04 ,  C07D405/04 ,  C07D409/14 ,  C07D491/048 ,  C07D495/04

Abstract: Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

Abstract translation: 本文提供噻吩化合物，其合成方法，包含该化合物的药物组合物及其使用方法。 本文提供的化合物可用于治疗，预防和/或治疗各种神经障碍，包括但不限于精神病和精神分裂症。